Phase 1/2Completed
A Safety and Effectiveness Pilot Study of PRF-108 and PRF-110 in Healthy Volunteers
A Single-center, Randomized, Placebo-controlled, Double-blind, Single-dose, Efficacy of PRF-108 4% and PRF-110 4% Versus Ropivacaine Solution 0.5% in an Experimental Pain Model
- Sponsor
- PainReform LTD (Industry)
- Enrollment
- 15 enrolled
- Conditions
- Pain
- Interventions
- PRF-108; Placebo; Ropivacaine; PRF-110
- Ages
- adults
- Registry
- NCT00883194
Full record on ClinicalTrials.gov
From the registry
This is a clinical study testing PRF-108 and PRF-110 (a new extended release 4% gel formulations of ropivacaine) in an experimentally induced pain model in healthy volunteers. PRF-108 and PRF-110 are designed to deliver slow release of ropivacaine over 72 hours.
Primary outcomes
- The duration of analgesia
History
Last registry update
Primary completion
Started
Registered